COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:

Key Record Dates Identifier: NCT03452137
Brief Title: A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

First Submitted : February 25, 2018
First Submitted that Met QC Criteria : February 28, 2018
First Posted : March 2, 2018

Last Update Submitted that Met QC Criteria : June 22, 2020
Last Update Posted : June 24, 2020